| Literature DB >> 26990957 |
V Sallinen1,2, E A Akl3,4, J J You4,5, A Agarwal4,6, S Shoucair7, P O Vandvik8, T Agoritsas4,9, D Heels-Ansdell4, G H Guyatt4,5, K A O Tikkinen10.
Abstract
BACKGROUND: For more than a century, appendicectomy has been the treatment of choice for appendicitis. Recent trials have challenged this view. This study assessed the benefits and harms of antibiotic therapy compared with appendicectomy in patients with non-perforated appendicitis.Entities:
Mesh:
Substances:
Year: 2016 PMID: 26990957 PMCID: PMC5069642 DOI: 10.1002/bjs.10147
Source DB: PubMed Journal: Br J Surg ISSN: 0007-1323 Impact factor: 6.939
Figure 1Flow chart showing selection of articles for review. WHO, World Health Organization; ICTRP, International Clinical Trials Registry Platform Search Portal
Characteristics of the included studies
| Reference | Study design | Participants | Intervention (antibiotic therapy) | Control (appendicectomy) | Outcomes assessed | Funding and conflict of interest statement |
|---|---|---|---|---|---|---|
| Eriksson and Granström8 | Single‐centre randomized trial | Patients ( |
Intravenous cefotaxime 2 g twice daily and tinidazole 800 mg once daily for 2 days, followed by oral ofloxacin 200 mg and tinidazole 500 mg twice daily for 8 days |
Open appendicectomy (100%) |
Appendicectomy rate within index admission |
Funding: Karolinska Institute, Swedish Hoechst, Pfizer, Mutual Group Life Insurance Company Förenade Liv |
| Salminen | Multicentre randomized trial | Patients ( |
Intravenous ertapenem sodium 1 g once daily for 3 days, followed by oral levofloxacin 500 mg once daily and metronidazole 500 mg three times per day for 7 days |
Open (94%) or laparoscopic (6%) appendicectomy with prophylactic antibiotics |
Primary outcome |
Funding: Government research grant (EVO Foundation) awarded to Turku University Hospital |
| Styrud | Multicentre randomized trial | Men ( |
Intravenous cefotaxime 2 g twice daily and tinidazole 800 mg once daily for 2 days, followed by oral ofloxacin 200 mg and tinidazole 500 mg twice daily for 10 days |
Open (94%) or laparoscopic (6%) appendicectomy |
Appendicectomy rate within index admission |
Funding: Swedish Society of Medicine, Karolinska Institute, Wallenius Corporation, Aventis Pharma |
| Svensson | Single‐centre randomized (pilot) trial |
Children ( |
Intravenous meropenem 10 mg/kg three times daily and metronidazole 20 mg/kg once daily for at least 48 h. Once the child was well clinically and tolerating oral intake, antibiotics continued with oral ciprofloxacin 20 mg/kg twice daily and metronidazole 20 mg/kg once daily for 8 days | Laparoscopic appendectomy (100 per cent) Prophylactic antibiotics given to all. Intravenous antibiotic continued for 24 h to patients with gangrenous appendicitis and for 3 days in those with perforated appendicitis |
Primary outcome: resolution of symptoms without significant complications (defined as length of stay over 7 days, abscess, need for surgery within 48 h (antibiotic group only), recurrence of appendicitis within 3 months, or negative appendicectomy). |
Funding: Crown Princess Lovisa's Foundation, the Hirsch Foundation |
| Vons | Multicentre randomized trial | Patients ( |
Amoxicillin plus clavulanic acid 3–4 g per day for 8–15 days, intravenously to those with nausea or vomiting, and orally to all others |
Open (34%) or laparoscopic (66%) appendicectomy with single‐dose prophylactic antibiotics |
Primary outcome: occurrence of peritonitis within 30 days of initial treatment (defined as perforated appendicitis in antibiotic group, postoperative peritonitis in appendicectomy group) |
Funding: French Ministry of Health, Programme Hospitalier de Recherche Clinique 2002 |
CRP, C‐reactive protein; WBC, white blood cell count; VAS, visual analogue scale.
Outcome prespecified as a secondary outcome but no data presented in publication.
Risk of bias
| Reference | Random sequence generation | Allocation concealment | Blinding | Completeness of data |
|---|---|---|---|---|
| Eriksson and Granström8 | + | – | – | + |
| Salminen | + | + | – | + |
| Styrud | + | + | – | – |
| Svensson | + | + | – | + |
| Vons | + | + | – | – |
+, Low risk of bias; −, high risk of bias.
GRADE evidence profile: antibiotic therapy versus appendicectomy for acute non‐perforated appendicitis
| No. of patients with data | Quality assessment | Summary of findings | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Study event rates | Absolute risk difference | Certainty in estimates | ||||||||
| Risk of bias | Inconsistency | Indirectness | Imprecision | Publication bias | Antibiotic therapy | Appendicectomy | ||||
| Major complications | ||||||||||
|
999 (5) | Serious limitations: major and minor complications likely under‐reported in antibiotics group | No serious limitations | No serious limitations | Serious limitations: 95% confidence interval crosses 0, indicating no difference | Undetected | 25 of 510 (4·9) | 41 of 489 (8·4) |
−2·6 (−6·3, 1·1)% | Low | |
| Minor complications | ||||||||||
|
999 (5) | Serious limitations: major and minor complications likely under‐reported in antibiotics group | Serious limitations: inconsistent forest plot estimates | No serious limitations | Serious limitations: 95% confidence interval crosses 0, indicating no difference | Undetected | 11 of 510 (2·2) | 61 of 489 (12·5) |
−7·2 (−18·1, 3·8)% | Very low | |
| Recurrence of appendicitis | ||||||||||
|
999 (5) | No serious limitations | No serious limitations | No serious limitations | No serious limitations | Undetected | 114 of 510 (22·4) |
0 of 489 |
22·6 (15·6 to 30·4)% | High | |
| Rate of appendicectomy within 1 month | ||||||||||
|
1112 (5) | No serious limitations | No serious limitations | No serious limitations | No serious limitations | Undetected | 47 of 550 (8·5) |
561 of 562 |
91·8 (88·2, 94·8)% | High | |
| Length of hospital stay | ||||||||||
|
1100 (5) | No serious limitations | No serious limitations | Serious limitations: most patients operated on using open approach; laparoscopic approach would shorten length of hospital stay | No serious limitations | Undetected |
0·41 (0·26 to 0·57) days | Moderate | |||
| Length of sick leave | ||||||||||
|
1017 (3) | No serious limitations | Serious limitations: inconsistent forest plot estimates | Serious limitations: most patients operated on using open approach; laparoscopic approach would shorten length of sick leave | Serious limitations: 95% confidence interval crosses 0, indicating no difference | Undetected |
−3·58 (−8·27, 1·11) days | Very low | |||
Values in parentheses are percentages unless indicated otherwise; values are
number of studies and
95 per cent confidence interval.
Figure 2Forest plot showing absolute risk difference in major complications in antibiotic therapy versus appendicectomy group. Risk differences are shown with 95 per cent c.i.
Figure 3Forest plot showing absolute risk difference in minor complications in antibiotic therapy versus appendicectomy group. Risk differences are shown with 95 per cent c.i.
Figure 4Forest plot showing mean difference in length of hospital stay in antibiotic therapy versus appendicectomy group. Mean differences are shown with 95 per cent c.i. *Values are mean(s.d.)
Figure 5Forest plot showing mean difference in length of sick leave in antibiotic therapy versus appendicectomy group. Mean differences are shown with 95 per cent c.i. *Values are mean(s.d.)